课题基金 / 基金详情

PHASE I/II MULTICENTER, OPEN LABEL STUDY OF THE EFFICACY OF PROLEASE HGH

PHASE I/II MULTICENTER, OPEN LABEL STUDY OF THE EFFICACY OF PROLEASE HGH
PROLEASE HGH 功效的 I/II 期多中心、开放标签研究
批准号：
6118427
负责人：
MITCHELL GEFFNER
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118427
关键词：
child (0-11) clinical research clinical trial phase I drug screening /evaluation endocrine disorder chemotherapy hormone therapy human subject human therapy evaluation longitudinal human study pediatric pharmacology pituitary dwarfism postnatal growth disorder somatotropin

项目摘要

项目成果

MITCHELL GEFFNER的其他基金

相似基金

相关文献

中文摘要
翻译
这项为期6个月的I/II期研究的具体目的是证明新型hGH缓释制剂治疗GH缺乏症儿童生长障碍的安全性和疗效。 将使用3个月和6个月的年生长率评估疗效。
英文摘要
The specific aim of this 6-month phase I/II study is to demonstrate the safety and efficacy of a new sustained-release formulation of hGH in the treatment of growth failure in children with GH deficiency. Efficacy will be assessed using 3 and 6 month annualized growth rates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EVAL OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND ADRENOMEDULLARY FUNCTION
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT
CLINICAL TRIAL: STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D
STUDIES TO TREAT OR PREVENT PEDIATRIC TYPE 2 DIABETES (STOPP-T2D): TREATMENT
海外基金